Showing results (1-10 of 77) with videos related to
Sort By:
Pageof 8
Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie|September 4, 2009
Optimizing the benefit to risk ratio of medical therapy of inflammatory bowel diseasesG Van AsscheExpert Opinion on Investigational Drugs|November 4, 2000
Anti-TNF agents in Crohn's diseaseG Van Assche, P RutgeertsMinerva Gastroenterologica E Dietologica|July 23, 2013
Is there a therapeutic window of opportunity in early inflammatory bowel disease? Early stage inflammatory bowel disease: the actual managementD Kevans, G Van AsscheGastroenterology|September 1, 1996
Leukemia inhibitory factor mediates cytokine-induced suppression of myenteric neurotransmitter release from rat intestineG Van Assche, S M CollinsAlimentary Pharmacology & Therapeutics|January 31, 2006
Review article: Infliximab therapy for inflammatory bowel disease--seven years onP Rutgeerts, G Van Assche, S VermeireAlimentary Pharmacology & Therapeutics|January 19, 2007
Review article: Altering the natural history of Crohn's disease--evidence for and against current therapiesS Vermeire, G van Assche, P RutgeertsGut|February 14, 2006
Laboratory markers in IBD: useful, magic, or unnecessary toys?S Vermeire, G Van Assche, P RutgeertsMinerva Gastroenterologica E Dietologica|October 4, 2007
Emerging biological treatments in inflammatory bowel diseasesG van Assche, S Vermeire, P RutgeertsDigestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 28, 2007
Perianal Crohn's disease: classification and clinical evaluationS Vermeire, G Van Assche, P RutgeertsNature Reviews. Gastroenterology & Hepatology|February 6, 2010
The potential for disease modification in Crohn's diseaseG Van Assche, Séverine Vermeire, Paul RutgeertsPageof 8